Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Nov 23;10(6):e01024. doi: 10.1002/prp2.1024

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 AbbVie Inc. Pharmacology Research & Perspectives published by British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics and John Wiley & Sons Ltd.

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

Mean ± SD sirolimus single‐dose blood concentration‐time profiles with or without co‐administration of the ritonavir‐containing 3D regimen. On Period 1 Day 1, a single dose of sirolimus 2 mg was administered. In Period 2, multiple doses of the 3D regimen (ombitasvir/paritaprevir/ritonavir 25/150/100 mg QD plus dasabuvir 250 mg BID) were administered on Day 1 through Day 34, with a single dose of sirolimus 0.5 mg co‐administered on Day 15. P1D1, Period 1 Day 1; P2D15, Period 2 Day 15; SD, standard deviation.